Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(23):470.
doi: 10.21037/atm.2017.09.22.

Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes

Hidekatsu Yanai  1
Affiliations
Editorial

Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes

Hidekatsu Yanai. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The change in estimated glomerular filtration rate (eGFR) and the possible mechanisms for improvement in heart failure due to sodium-glucose cotransporter 2 inhibitors (SGLT2i). The graph was modified from Figure 1 in (9).
See this image and copyright information in PMC

Comment on

References

    1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. 10.1056/NEJMoa1504720 - DOI - PubMed
    1. Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol 2017;54:19-36. 10.1007/s00592-016-0892-7 - DOI - PubMed
    1. Saad M, Mahmoud AN, Elgendy IY, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol 2017;228:352-8. 10.1016/j.ijcard.2016.11.181 - DOI - PubMed
    1. Tang H, Fang Z, Wang T, et al. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol 2016;118:1774-80. 10.1016/j.amjcard.2016.08.061 - DOI - PubMed
    1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57. 10.1056/NEJMoa1611925 - DOI - PubMed

LinkOut - more resources